Trial Profile
A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary) ; Vorasidenib (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Biomarker; Pharmacodynamics
- Acronyms Window
- Sponsors Agios Pharmaceuticals
- 22 Feb 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
- 08 Jun 2021 Results assessing biological impact of D-2-hydroxyglutarate suppression on tumors and tumor immune microenvironment presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2021 According to a Servier media release, Ingo Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center, is an investigator for the study.